JB Chemicals & Pharmaceuticals Ltd. (JB Pharma), one of the fastest growing pharmaceutical companies in India, announced its Q1 FY23 results by recording a revenue growth of 30% to reach Rs. 785 crore.

For the first quarter ended 30th June 2022, the company recorded revenue of Rs. 785 crore as compared to Rs. 606 crore, registering growth of 30% over the corresponding quarter. Operating EBITDA (Earnings Before Interest Depreciation and Taxes) increased by 16% to Rs. 190 crore as compared to Rs. 164 crore. Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23.

Commenting on financial results, Nikhil Chopra, CEO and Wholetime Director, JB Pharma said, “Our operating performance in FY23 started on a strong note. We continued the momentum in our domestic business, registering market-beating growth and achieving a new milestone in quarterly run-rate revenue of over Rs. 400 crore."

"Integration of Sanzyme's product range and Azmarda have progressed as per plan. We also completed the acquisition of a portfolio of paediatric brands which will enable us to offer a more comprehensive product basket to paediatricians, helping us to serve them better. International business also saw strong growth with a robust order pipeline and out-performance in the CMO segment. With this start, I believe we have built good momentum for the year ahead and together with our continued focus on productivity enhancement and cost optimisation, we are confident of delivering profitable growth,” added Chopra.